drugset / Trial / NCT06372717
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).
Timeline
- Start
- 2024-06-04
- Primary completion
- 2027-03-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APL-4098 | Unknown | — | Oral |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Venetoclax | Small molecule | — | Oral |